An interventional study of ECMT-100 in Fistula in Ano, sponsored by ECM Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by ECM Therapeutics, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.
Among the 20 studies in Rectal Fistula with a site in United States, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, and was the 17th registered.
170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.
Browse Rectal Fistula studies →7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:
Signum Surgical USA Inc. · Sites in United States
Ages 18–75
RedDress Ltd. · Sites in United States, Israel
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Aroa Biosurgery Limited · Sites in United States
Ages 18+
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 66 across 116 interventional studies indexed under Rectal Fistula.
Median enrollment 21 across the 15 interventional studies, 79 across the 5 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with ECM Therapeutics, Inc. as lead sponsor.
ECM Therapeutics, Inc. has 1 study filed under Rectal Fistula — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Fistula with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04190862Weill Medical College of Cornell UniversityE-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas | 2026-12-30 |
| NCT07021742Signum Surgical USA Inc.BioHealx® Anal Fistula Device Post Market Surveillance Study | 2027-02 |
| NCT07035925ECM Therapeutics, Inc.Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas | 2027-02-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Rectal Fistula with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety and Efficacy of ECMT-100 for the Treatment of Anorectal Fistulas
ECMT-100 is a colloidal hydrogel derived from extracellular matrix (ECM), formulated to adhere to sub-epithelial soft tissue and allow for filling of anorectal fistulas to reinforce and promote fistula tract closure. ECMT-100 is a medical device and should be administered via catheter within the fistula tract following curettage of the tract, with draining setons used preoperatively.
ECMT-100 is a mucoadhesive hydrogel composed of ECM formulated to adhere to the gastrointestinal mucosa, fill the transsphincteric fistula tract, and promote tract closure by allowing for timely host tissue integration without fecal incontinence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECMT-100 Subjects will be followed for 12 months following last treatment with ECMT-100. Subjects are eligible for one repeat treatment as determined by the clinician/investigator at or prior to the 6-month visit.
Device: ECMT-100
Colloidal hydrogel
Adverse Events
Number of Adverse Events
Time frame: 12 months from treatment
Percentage of Subjects in whom external openings of the fistula have closed
Physical exam to confirm closure and absence of discharge
Time frame: 12 months from treatment
Changes in Fecal Incontinence
Wexner Score - Cleveland Clinic Fecal Incontinence Score; changes from baseline
Time frame: 12 months from treatment
Changes in Quality of Life
Medical Outcomes Study Questionnaire Short Form 36; changes from baseline
Time frame: 12 months from treatment
Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.
Of 58 interventional studies with no phase under Rectal Fistula, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.